Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Mar;309(3):789-799.
doi: 10.1007/s00404-023-07149-8. Epub 2023 Jul 16.

The role of L1CAM as predictor of poor prognosis in stage I endometrial cancer: a systematic review and meta-analysis

Andrea Giannini #  1 , Ottavia D'Oria #  2 , Giacomo Corrado  3 , Valentina Bruno  4 , Isabella Sperduti  5 , Giorgio Bogani  6 , Antonio Simone Laganà  7 , Vito Chiantera  7 , Donatella Caserta  8 , Enrico Vizza  4
Affiliations
Meta-Analysis

The role of L1CAM as predictor of poor prognosis in stage I endometrial cancer: a systematic review and meta-analysis

Andrea Giannini et al. Arch Gynecol Obstet. 2024 Mar.

Abstract

Introduction: Molecular and genomic profiling in endometrial cancer is increasing popularity. L1 cell adhesion molecule (L1CAM) is frequently mutated in endometrial cancer. In this paper, we aim to evaluate the prognostic role of L1CAM in patients with stage I endometrial cancer.

Methods: We performed a systematic review and meta-analysis searching in PubMed (MEDLINE), EMBASE, and Web of Science database to identify studies reporting the expression of L1CAM in endometrial cancer. The primary endpoint measure was to assess and evaluate the impact of L1CAM on survival outcomes. This study was performed according to the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P) statement.

Results: Five studies were included. The pooled results suggested that L1CAM expression influences survival outcomes in stage I endometrial cancer. High L1CAM expression correlated with worse disease-free survival (HR 4.11, 95% CI 1.02-16.59, p = 0.047) and overall survival (HR 3.62, 95% CI 1.32-9.31, p = 0.012). High L1CAM level was also associated with a more aggressive FIGO grade and with older age.

Conclusion: This systematic review supported that L1CAM have a prognostic role in stage I endometrial cancer, thus providing a potential useful tool for tailoring the need of adjuvant therapy.

Keywords: Biomarkers; Endometrial cancer; L1 cell adhesion molecule (L1CAM); Molecular profiling; Target therapies.

PubMed Disclaimer

References

    1. Moos M, Tacke R, Scherer H, Teplow D, Fruh K, Schachner M (1988) Neural adhesion molecule L1 as a member of the immunoglobulin superfamily with binding domains similar to fibronectin. Nature 334:701–703 - PubMed - DOI
    1. Kamiguchi H, Hlavin ML, Lemmon V (1998) Role of L1 in neural development: what the knockouts tell us. Mol Cell Neurosci 12:48–55 - PubMed - DOI
    1. Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Smirnov A et al (2003) L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet 362:869–875 - PubMed - DOI
    1. Zecchini S, Bianchi M, Colombo N, Fasani R, Goisis G, Casadio C et al (2008) The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Cancer Res 68:1110–1118 - PubMed - DOI
    1. Zeimet G, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA et al (2013) L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst 105:1142–1150 - PubMed - DOI

Substances

LinkOut - more resources